SCHEMBL24317445

SCHEMBL24317445

CCOC(=O)c1cc(Cc2ccc3c4c(cccc24)NC3=O)ccc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 6/20 0.42
PDE3A Q14432 6/20 0.42
KDM4E B2RXH2 4/20 0.40
HPGD P15428 3/20 0.40
HSD17B10 Q99714 3/20 0.40
MAPT P10636 3/20 0.40
MAPK1 P28482 2/20 0.40
USP2 O75604 2/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 2/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRB2 P47870 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24317747 0.84 CYP4F2 (0.45) PDE3BPDE3AKDM4EHPGDHSD17B10
SCHEMBL24317388 0.84 RXFP1 (0.43) KDM4EHPGDHSD17B10MAPTMAPK1
SCHEMBL11317546 0.79 KDM4E (0.47) KDM4EHPGDHSD17B10MAPTMAPK1
SCHEMBL24317439 0.78 PARP1 (0.41) KDM4EHPGDHSD17B10USP2ALOX15
SCHEMBL24317881 0.75 MAPT (0.53) KDM4EHPGDHSD17B10MAPTLMNA
SCHEMBL29532752 0.75 TDP1 (0.42) PDE3BPDE3AKDM4EHPGDMAPT
SCHEMBL24317769 0.75 TDP1 (0.42) PDE3BPDE3AKDM4EHPGDMAPT
SCHEMBL24317767 0.74 CRBN (0.41) TSHRALDH1A1CYP1A2
SCHEMBL11322480 0.74 KDM4E (0.53) KDM4EHPGDHSD17B10MAPTMAPK1
SCHEMBL24317645 0.74 MAPT (0.48) KDM4EHPGDHSD17B10MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 PDE3B 3910/4885PDE3A 4139/4885KDM4E 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.